tiprankstipranks
Trending News
More News >
Rebus Holdings (RBSH)
OTHER OTC:RBSH
US Market

Rebus Holdings (RBSH) Price & Analysis

Compare
45 Followers

RBSH Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

<0.01%100.00%
Insiders
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

RBSH FAQ

What was Rebus Holdings’s price range in the past 12 months?
Currently, no data Available
What is Rebus Holdings’s market cap?
Rebus Holdings’s market cap is $3.21K.
    When is Rebus Holdings’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Rebus Holdings’s earnings last quarter?
    Rebus Holdings released its earnings results on Nov 24, 2020. The company reported -$0.019 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.019.
      Is Rebus Holdings overvalued?
      According to Wall Street analysts Rebus Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Rebus Holdings pay dividends?
        Rebus Holdings does not currently pay dividends.
        What is Rebus Holdings’s EPS estimate?
        Rebus Holdings’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Rebus Holdings have?
        Rebus Holdings has 32,132,908 shares outstanding.
          What happened to Rebus Holdings’s price movement after its last earnings report?
          Rebus Holdings reported an EPS of -$0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
            Which hedge fund is a major shareholder of Rebus Holdings?
            Currently, no hedge funds are holding shares in RBSH

            Company Description

            Rebus Holdings

            Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.
            Similar Stocks
            Company
            Price & Change
            Follow
            Hepion Pharmaceuticals
            Windtree Therapeutics
            Vincerx Pharma Inc
            Universe Pharmaceuticals
            Sharps Technology, Inc.
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis